AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
AMZN   2,442.37 (+1.72%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
AMZN   2,442.37 (+1.72%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
AMZN   2,442.37 (+1.72%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
AMZN   2,442.37 (+1.72%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

NASDAQ:MGNXMacroGenics Stock Price, Forecast & News

$19.24
-3.76 (-16.35 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.43
Now: $19.24
$21.21
50-Day Range
$5.20
MA: $14.43
$27.15
52-Week Range
$4.04
Now: $19.24
$29.50
Volume3.50 million shs
Average Volume8.00 million shs
Market Capitalization$945.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Read More
MacroGenics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.19 million
Book Value$3.88 per share

Profitability

Net Income$-151,810,000.00
Net Margins-222.14%

Miscellaneous

Employees364
Market Cap$945.45 million
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

How has MacroGenics' stock been impacted by COVID-19 (Coronavirus)?

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MGNX stock has increased by 196.5% and is now trading at $19.24. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MacroGenics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating, 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for MacroGenics.

How were MacroGenics' earnings last quarter?

MacroGenics Inc (NASDAQ:MGNX) posted its earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($0.91) EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $0.10. The biopharmaceutical company had revenue of $13.68 million for the quarter, compared to analysts' expectations of $7.43 million. MacroGenics had a negative return on equity of 62.43% and a negative net margin of 222.14%. View MacroGenics' earnings history.

What price target have analysts set for MGNX?

13 analysts have issued 12-month target prices for MacroGenics' shares. Their forecasts range from $6.00 to $50.00. On average, they expect MacroGenics' share price to reach $28.50 in the next twelve months. This suggests a possible upside of 48.1% from the stock's current price. View analysts' price targets for MacroGenics.

Has MacroGenics been receiving favorable news coverage?

News articles about MGNX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MacroGenics earned a coverage optimism score of 0.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutMacroGenics.

Are investors shorting MacroGenics?

MacroGenics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 2,860,000 shares, a decrease of 11.2% from the April 30th total of 3,220,000 shares. Based on an average daily volume of 2,620,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 6.6% of the shares of the stock are sold short. View MacroGenics' Current Options Chain.

Who are some of MacroGenics' key competitors?

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Bausch Health Companies (BHC), Epizyme (EPZM), Incyte (INCY), Karyopharm Therapeutics (KPTI) and Nektar Therapeutics (NKTR).

Who are MacroGenics' key executives?

MacroGenics' management team includes the following people:
  • Dr. Scott Koenig, CEO, Pres & Director (Age 67)
  • Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)
  • Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)
  • Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57)

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.72%), Invesco Ltd. (9.12%), Wasatch Advisors Inc. (5.32%), State Street Corp (3.90%), Rhenman & Partners Asset Management AB (2.04%) and Nuveen Asset Management LLC (1.81%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View institutional ownership trends for MacroGenics.

Which major investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Rhenman & Partners Asset Management AB, Morgan Stanley, Spark Investment Management LLC, Principal Financial Group Inc., Two Sigma Investments LP, Deutsche Bank AG, and GSA Capital Partners LLP. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, and Thomas Spitznagel. View insider buying and selling activity for MacroGenics.

Which major investors are buying MacroGenics stock?

MGNX stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Ikarian Capital LLC, Nuveen Asset Management LLC, Acadian Asset Management LLC, Russell Investments Group Ltd., Thrivent Financial for Lutherans, BlackRock Inc., and Geode Capital Management LLC. View insider buying and selling activity for MacroGenics.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $19.24.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $945.45 million and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe.

What is MacroGenics' official website?

The official website for MacroGenics is www.macrogenics.com.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.